Alexander Mulamula, MD
Pulmonary Disease · Baton Rouge, LANPI 1124244389
Payments from drug & device makers
What this record shows
This record is dominated by education: $8,500 of the $12,342 with a category attached, or 68.9%. Intuitive Surgical accounts for 80.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $6,747 and has fallen 50.8% since, to $3,320 in 2025.
Across 38 payments — averaging $324.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Astrazeneca UK Limited$1K
- Inari Medical, Inc.$622
- Boehringer Ingelheim$117
- Actelion Pharmaceuticals US, Inc.$93
- United Therapeutics Corporation$72
- plus $96 from 5 others
Across 11 payments — averaging $23,069 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$133K
- AstraZeneca$121K
What the payments were for
- Travel & lodging$2,44020%
- Food & beverage$1,40211%
- Education$8,50069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $9,877 |
| Astrazeneca UK Limited | 5 | $1,465 |
| Inari Medical, Inc. | 5 | $622 |
| Boehringer Ingelheim | 1 | $117 |
| Actelion Pharmaceuticals US, Inc. | 3 | $93 |
| United Therapeutics Corporation | 3 | $72 |
| Viatris Specialty LLC | 1 | $32 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Bayer | 1 | $16 |
| Veran Medical Technologies, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,342 in reported general payments places this provider in the 80th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 26 | $664,202 |
| OfevNintedanib Esylate | 48 | $617,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 520 | $462,595 |
| XyremSodium Oxybate | 15 | $321,624 |
| UptraviSelexipag | 13 | $291,948 |
| Ambrisentan | 14 | $146,008 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 102 | $69,381 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 97 | $55,079 |
| Spiriva RespimatTiotropium Bromide | 82 | $53,971 |
| NucalaMepolizumab | 14 | $51,107 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $44,329 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $40,498 |
| Tadalafil | 22 | $37,035 |
| Arnuity ElliptaFluticasone Furoate | 123 | $35,569 |
| Advair HfaFluticasone Propion/Salmeterol | 45 | $27,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $117 | $740,779232 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $18 | $648,679835 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Bosentan | $93 | $307,06926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Baton Rouge
- Hollis O NealBaton Rouge$418K
- Robert HinkleBaton Rouge$19K
- Tarek AbdallahBaton Rouge$12K
- Brad VincentBaton Rouge$12K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
- Nicole LapinelNew Orleans$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.